IGFBP-3 enhances irinotecan efficacy in colorectal cancer via ROS-mediated apoptosis and β-catenin suppression
Elahe Gharehkhani, Mohammad Karami, Abouzar Bagheri, Mahboube Rahmati Kukandeh, Mohammad Shokrzadeh · 2026
Read IGFBP-3 enhances irinotecan efficacy in colorectal cancer via ROS-mediated apoptosis and β-catenin suppression by Elahe Gharehkhani, Mohammad Karami, Abouzar Bagheri, Mahboube Rahmati Kukandeh, Mohammad Shokrzadeh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13441036.txt.
Description
Elahe Gharehkhani and colleagues pair a natural growth-control protein with a standard bowel cancer drug to see whether the drug works harder, reporting cell work in 2026. Irinotecan treats advanced colorectal cancer, while IGFBP-3, a binding protein governed by p53, can push tumour cells toward death. SW480 cancer cells received each agent alone and together. Combination software scored whether the pair cooperated or merely added up.
The pair scored as truly synergistic, killing more than either alone. Combined treatment raised cell suicide rates, froze more cells at the pre-division checkpoint, and flooded cells with damaging oxygen radicals while draining their antioxidant store. Death-promoting Bax rose, while protective Bcl2 and the growth driver beta-catenin both fell. The authors propose IGFBP-3 as a chemo-boosting partner, with safety checks on normal cells still owed.
Catalog record
| CREATOR | Elahe Gharehkhani, Mohammad Karami, Abouzar Bagheri, Mahboube Rahmati Kukandeh, Mohammad Shokrzadeh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |